Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) posted revenue of CA$734,028 for the second quarter ended June 30, 2026, up 43% from CA$512,756 in the same period of 2025.
Revenue was broadly consistent with the CA$737,103 reported in the first quarter of 2026. Completed U.S. patient visits rose 196% quarter over quarter to 3,911 from 1,319.
Why the Q2 Results Matter for Investors
The sharp rise in U.S. patient volume shows early traction from new in-network payer agreements. These contracts now provide access to roughly 24 million covered lives across California, Maryland, and New York State.
The company noted that some U.S. revenue is booked on a cash basis, so the full impact of higher visit counts will appear in later quarters.
Platform Advantages and Payer Footprint
Rocket Doctor built its digital health platform with physicians, which helps align tools with clinical workflows.
Active U.S. clinicians grew from 19 to 30 during the quarter, while 80 providers sit on the roster, with most advancing through credentialing.
In Canada, completed visits rose 23% year over year to 45,766.
Key Growth Assets and Near-Term Catalysts
During the quarter, the company added its first U.S. value-based primary care agreement and expanded coverage in Maryland. Post-quarter moves include SOC 2 Type 1 compliance, an extended EngageWell partnership in New York City, and additional in-network access for more than 100,000 members in New York. The firm also closed two tranches of convertible debenture financing for roughly CA$3.26 million.
Other second-quarter developments included a Digital Health Observership Program with the University of Toronto, a marketing partnership with Rick Ware Racing and FINTEKK AP, and a partnership with Mindstride AI to provide after-hours and overflow physician coverage in Ontario, Alberta, and British Columbia. Also during the quarter, Treatment.com, the U.S. subsidiary, secured US$250,000 in Year 2 NIH funding.
Telehealth Sector Timing
J.P. Morgan Payments described telehealth as part of a broader shift toward digitalized healthcare, with virtual care increasingly combining remote medical services, connected devices, and digital payment infrastructure. The firm cited Grand View Research, which valued the global telehealth market at US$83.5 billion in 2022, and McKinsey's estimate that US$250 billion of current U.S. healthcare spending has the potential to be virtualized.
An August 17 report from Fortune Business Insights valued the global telehealth market at US$186.41 billion in 2025 and estimated it at US$219.31 billion in 2026. North America accounted for 45.29% of the global market in 2025.
A separate U.S. telehealth market report published in August by Market.us described virtual care as increasingly incorporated into routine healthcare delivery across primary care, chronic disease management, behavioral health, follow-up consultations, and specialty services.
Analyst Views and Valuation Context
1Technical analyst Stewart Thomson highlighted Rocket Doctor AI's growing digital health platform on March 17, and rated the stock a Strong Speculative Buy with targets of CA$0.80 short term, CA$1.00 medium term, and CA$1.60 long term.
Fundamental Research Corp. analyst Sid Rajeev reiterated a Buy rating and CA$1.55 target on June 11, 2026, citing U.S. expansion and rising patient volumes.
Streetwise Ownership Overview*
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 08/21/25 | TRUE:CSE | 1 | AIDR:CSE | 1 |
| 07/14/23 | TRUE:CSE | 10 | TRUE:CSE | 1 |
Share Structure and Liquidity2
Rocket Doctor AI Inc. has a market cap of approximately CA$59.61 million, with 101.04 million shares outstanding. The 52-week range is CA$0.50-CA$0.98.
Management and insiders own 4.24% of shares. Cash and cash equivalents stood at CA$0.95 million as of June 30, 2026.
Key Investor Takeaways
- Q2 revenue rose 43% year over year to CA$734,028, while U.S. patient visits jumped 196% quarter over quarter.
- In-network payer agreements now cover approximately 24 million lives in three states, with Florida and Texas in the expansion pipeline.
- 80 providers are on the roster, with the majority still advancing through credentialing, which could expand the company's clinical capacity as more providers become in-network.
- Gross margin was 65% as the company scales its U.S. platform; timing differences in revenue recognition are expected to resolve in later quarters.
- Post-quarter financing added roughly CA$3.26 million and new payer access for more than 100,000 members in New York.
Common Questions from Investors
What drove the 196% increase in U.S. patient visits?
The rise reflects new payer agreements and growth in the active clinician network from 19 to 30 during the quarter.
How many covered lives are included in the current U.S. network?
Approximately 24 million covered lives across California, New York, and Maryland.
When will the full revenue impact of higher U.S. visits appear?
Certain U.S. revenues are recognized on a cash basis, so the company expects the impact to be recorded in future quarters.
What states are next for U.S. expansion?
Management has identified Florida and Texas among the states in the expansion pipeline.
What is the Global Library of Medicine?
It is an AI knowledge base developed with more than 25,000 hours of input from hundreds of clinicians and more than 10,000 expert medical reviews, covering over 1,000 diseases and 17,000 symptoms for integration into telehealth and other systems.
The company continues to execute on U.S. payer relationships and physician onboarding while the broader telehealth market expands. Retail investors should monitor quarterly patient volumes, new payer signings, and credentialing progress as key milestones.
| Want to be the first to know about interesting Life Sciences Tools & Diagnostics and Healthcare Services investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026
1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
2. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
